SGLT2 Plus GLP-1 Drug Beats SGLT2 Plus DPP-4 for Fatty Liver in Obese Mice
Combining empagliflozin with dulaglutide reduced fatty liver by 82% in obese mice, far outperforming the empagliflozin plus linagliptin combination.
Quick Facts
What This Study Found
High-fat diet versus control: liver triglycerides increased 82%, steatosis increased 850%, glucose intolerance increased 71%, insulin increased 98%, and insulin resistance increased 68%.
Both drug combinations improved all parameters compared to untreated obese mice:
- Empagliflozin + linagliptin: glucose intolerance -60%, insulin -61%, insulin resistance -46%, TAG -61%, steatosis -58%
- Empagliflozin + dulaglutide: glucose intolerance -71%, insulin -58%, insulin resistance -62%, TAG -61%, steatosis -82%
Principal component analysis clearly separated the groups: the GLP-1 combination was furthest from the disease group, while the DPP-4 combination fell between control and the GLP-1 group.
Key Numbers
- 40 mice (10 per group, 4 groups)
- Diet duration: 12 weeks high-fat
- Treatment duration: 3 weeks
- E+D vs HF: steatosis -82%, insulin resistance -62%, glucose intolerance -71%, TAG -61%
- E+L vs HF: steatosis -58%, insulin resistance -46%, glucose intolerance -60%, TAG -61%
- PCA placed E+D opposite from HF (disease group)
How They Did This
Male C57BL/6J mice (3 months old) were fed control or high-fat diet for 12 weeks. Then treated for 3 additional weeks: control, high-fat untreated, high-fat + empagliflozin + linagliptin, or high-fat + empagliflozin + dulaglutide. 10 mice per group. Outcomes: liver triglycerides, steatosis histology, glucose tolerance, insulin levels, and gene expression for metabolism and mitochondrial biogenesis.
Why This Research Matters
Fatty liver disease affects 25% of the global population and over half of people with type 2 diabetes. Single-drug treatment is often insufficient. This study compares two realistic combination strategies and shows the GLP-1 combination is clearly superior. This informs clinical decision-making about which drugs to combine for diabetes patients with fatty liver.
The Bigger Picture
Fatty liver disease affects 25% of the global population and over half of diabetes patients. This study supports combining an SGLT2 inhibitor with a GLP-1 drug rather than a DPP-4 inhibitor for the most liver benefit.
What This Study Doesn't Tell Us
Tested in mice, not people. Only 3 weeks of treatment, which is short even for mice. The high-fat diet model creates MASLD but may not replicate all features of human disease. Dulaglutide and linagliptin were compared at standard doses, but dose equivalency across drug classes is difficult in animals. Gene expression changes were measured but functional validation was not performed.
Questions This Raises
- ?Would semaglutide or tirzepatide paired with an SGLT2i produce even better results?
- ?Is 3 weeks of treatment enough to draw conclusions about chronic disease?
Trust & Context
- Key Stat:
- 82% steatosis reduction The SGLT2i + GLP-1 combination reduced liver fat by 82% compared to untreated high-fat diet mice
- Evidence Grade:
- Rated preliminary: animal study with only 3 weeks of treatment and 10 mice per group. Results need confirmation in longer studies and humans.
- Study Age:
- Published in 2024. Directly relevant to ongoing clinical discussions about optimal combination therapy for metabolic disease.
- Original Title:
- Sodium-glucose cotransporter-2 inhibitor (SGLT2i) plus glucagon-like peptide type 1 receptor combination is more effective than SGLT2i plus dipeptidyl peptidase-4 inhibitor combination in treating obese mice metabolic dysfunction-associated steatotic liver disease (MASLD).
- Published In:
- Fundamental & clinical pharmacology, 38(6), 1059-1068 (2024)
- Authors:
- Reis-Barbosa, Pedro H(2), Mandarim-de-Lacerda, Carlos A(3)
- Database ID:
- RPEP-09141
Evidence Hierarchy
Frequently Asked Questions
What drug combination works best for fatty liver in diabetes?
In mice, combining an SGLT2 inhibitor (empagliflozin) with a GLP-1 drug (dulaglutide) reduced liver fat by 82%, far better than SGLT2i + DPP-4 inhibitor.
Can combination therapy treat fatty liver disease?
Single drugs often aren't enough. This study suggests the right combination — specifically SGLT2i plus GLP-1 — can dramatically reduce liver fat in animal models.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09141APA
Reis-Barbosa, Pedro H; Mandarim-de-Lacerda, Carlos A. (2024). Sodium-glucose cotransporter-2 inhibitor (SGLT2i) plus glucagon-like peptide type 1 receptor combination is more effective than SGLT2i plus dipeptidyl peptidase-4 inhibitor combination in treating obese mice metabolic dysfunction-associated steatotic liver disease (MASLD).. Fundamental & clinical pharmacology, 38(6), 1059-1068. https://doi.org/10.1111/fcp.13024
MLA
Reis-Barbosa, Pedro H, et al. "Sodium-glucose cotransporter-2 inhibitor (SGLT2i) plus glucagon-like peptide type 1 receptor combination is more effective than SGLT2i plus dipeptidyl peptidase-4 inhibitor combination in treating obese mice metabolic dysfunction-associated steatotic liver disease (MASLD).." Fundamental & clinical pharmacology, 2024. https://doi.org/10.1111/fcp.13024
RethinkPeptides
RethinkPeptides Research Database. "Sodium-glucose cotransporter-2 inhibitor (SGLT2i) plus gluca..." RPEP-09141. Retrieved from https://rethinkpeptides.com/research/reis-barbosa-2024-sodiumglucose-cotransporter2-inhibitor-sglt2i
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.